Development of nanosystems for active tumor targeting in photodynamic therapy

Autores
Ibarra, Luis Exequiel
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Cancer is one of the major public health problems worldwide. According to the International Agency for Research on Cancer, an estimated 19.3 million new cancer cases and almost 10 million cancer deaths occurred in 2020 [1]. Furthermore, the diagnosis and treatment of cancer have been hampered by the coronavirus disease 2019 (COVID-19) pandemic and it is expected to result in an increased cancer mortality over the next years due to a delay in the diagnoses, and also due to an interruption in the treatments that had been applied to cancer patients. For example, the U.S. National Cancer Institute estimated a 1% increase in deaths related to breast and colorectal cancer over the next 10 years, the equivalent of approximately 10,000 more deaths, due to the impact of the pandemic [2]. This highlights the need to continue in the search of new therapeutic compounds in order to reduce the chance of cancer recurrence after traditional treatments such as surgery and radiotherapy.Some of these new treatments could be used as primary or adjuvant therapeutic options, for instance, photodynamic therapy (PDT) arises as an improved treatment tool due to its highly effective, non-invasive and localized therapeutic action. Taking consideration of the selective action in the irradiation tumor area with PDT, and that it is a treatment that does not compromise other treatment options and presents reduced long-term morbidity when compared with chemotherapy or radiotherapy, this photo-assisted therapy is positioned as a main and/or adjuvant treatment in the fight against cancer. PDT has been approved by the Food Drug Administration (FDA), and also by other regulatory agencies around the world, to treat a variety of tumors and malignancies in the clinic [3]. For the success of PDT, three elements must converge in tumor cells: photosensitizer (PS) accumulation, light irradiation penetration and the presence of molecular oxygen. More of the recent developments regarding PDT have been made around the generation of new PSs.
Fil: Ibarra, Luis Exequiel. Universidad Nacional de Rio Cuarto. Facultad de Cs.exactas Fisicoquimicas y Naturales. Instituto de Biotecnologia Ambiental y Salud. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Conicet - Cordoba. Instituto de Biotecnologia Ambiental y Salud.; Argentina. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Departamento de Biología Molecular; Argentina
Materia
ACTIVE TARGETING
CANCER
DRUG DELIVERY
NANOPARTICLES
PHOTOSENSITIZERS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/202086

id CONICETDig_246decb2872fc1730d6fc3bd89c0b75a
oai_identifier_str oai:ri.conicet.gov.ar:11336/202086
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Development of nanosystems for active tumor targeting in photodynamic therapyIbarra, Luis ExequielACTIVE TARGETINGCANCERDRUG DELIVERYNANOPARTICLESPHOTOSENSITIZERShttps://purl.org/becyt/ford/2.10https://purl.org/becyt/ford/2Cancer is one of the major public health problems worldwide. According to the International Agency for Research on Cancer, an estimated 19.3 million new cancer cases and almost 10 million cancer deaths occurred in 2020 [1]. Furthermore, the diagnosis and treatment of cancer have been hampered by the coronavirus disease 2019 (COVID-19) pandemic and it is expected to result in an increased cancer mortality over the next years due to a delay in the diagnoses, and also due to an interruption in the treatments that had been applied to cancer patients. For example, the U.S. National Cancer Institute estimated a 1% increase in deaths related to breast and colorectal cancer over the next 10 years, the equivalent of approximately 10,000 more deaths, due to the impact of the pandemic [2]. This highlights the need to continue in the search of new therapeutic compounds in order to reduce the chance of cancer recurrence after traditional treatments such as surgery and radiotherapy.Some of these new treatments could be used as primary or adjuvant therapeutic options, for instance, photodynamic therapy (PDT) arises as an improved treatment tool due to its highly effective, non-invasive and localized therapeutic action. Taking consideration of the selective action in the irradiation tumor area with PDT, and that it is a treatment that does not compromise other treatment options and presents reduced long-term morbidity when compared with chemotherapy or radiotherapy, this photo-assisted therapy is positioned as a main and/or adjuvant treatment in the fight against cancer. PDT has been approved by the Food Drug Administration (FDA), and also by other regulatory agencies around the world, to treat a variety of tumors and malignancies in the clinic [3]. For the success of PDT, three elements must converge in tumor cells: photosensitizer (PS) accumulation, light irradiation penetration and the presence of molecular oxygen. More of the recent developments regarding PDT have been made around the generation of new PSs.Fil: Ibarra, Luis Exequiel. Universidad Nacional de Rio Cuarto. Facultad de Cs.exactas Fisicoquimicas y Naturales. Instituto de Biotecnologia Ambiental y Salud. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Conicet - Cordoba. Instituto de Biotecnologia Ambiental y Salud.; Argentina. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Departamento de Biología Molecular; ArgentinaNewlands Press Ltd2022-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/202086Ibarra, Luis Exequiel; Development of nanosystems for active tumor targeting in photodynamic therapy; Newlands Press Ltd; Therapeutic Delivery; 13; 2; 2-2022; 71-742041-59902041-6008CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4155/tde-2021-0083info:eu-repo/semantics/altIdentifier/url/https://www.future-science.com/doi/10.4155/tde-2021-0083info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T12:11:08Zoai:ri.conicet.gov.ar:11336/202086instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 12:11:09.169CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Development of nanosystems for active tumor targeting in photodynamic therapy
title Development of nanosystems for active tumor targeting in photodynamic therapy
spellingShingle Development of nanosystems for active tumor targeting in photodynamic therapy
Ibarra, Luis Exequiel
ACTIVE TARGETING
CANCER
DRUG DELIVERY
NANOPARTICLES
PHOTOSENSITIZERS
title_short Development of nanosystems for active tumor targeting in photodynamic therapy
title_full Development of nanosystems for active tumor targeting in photodynamic therapy
title_fullStr Development of nanosystems for active tumor targeting in photodynamic therapy
title_full_unstemmed Development of nanosystems for active tumor targeting in photodynamic therapy
title_sort Development of nanosystems for active tumor targeting in photodynamic therapy
dc.creator.none.fl_str_mv Ibarra, Luis Exequiel
author Ibarra, Luis Exequiel
author_facet Ibarra, Luis Exequiel
author_role author
dc.subject.none.fl_str_mv ACTIVE TARGETING
CANCER
DRUG DELIVERY
NANOPARTICLES
PHOTOSENSITIZERS
topic ACTIVE TARGETING
CANCER
DRUG DELIVERY
NANOPARTICLES
PHOTOSENSITIZERS
purl_subject.fl_str_mv https://purl.org/becyt/ford/2.10
https://purl.org/becyt/ford/2
dc.description.none.fl_txt_mv Cancer is one of the major public health problems worldwide. According to the International Agency for Research on Cancer, an estimated 19.3 million new cancer cases and almost 10 million cancer deaths occurred in 2020 [1]. Furthermore, the diagnosis and treatment of cancer have been hampered by the coronavirus disease 2019 (COVID-19) pandemic and it is expected to result in an increased cancer mortality over the next years due to a delay in the diagnoses, and also due to an interruption in the treatments that had been applied to cancer patients. For example, the U.S. National Cancer Institute estimated a 1% increase in deaths related to breast and colorectal cancer over the next 10 years, the equivalent of approximately 10,000 more deaths, due to the impact of the pandemic [2]. This highlights the need to continue in the search of new therapeutic compounds in order to reduce the chance of cancer recurrence after traditional treatments such as surgery and radiotherapy.Some of these new treatments could be used as primary or adjuvant therapeutic options, for instance, photodynamic therapy (PDT) arises as an improved treatment tool due to its highly effective, non-invasive and localized therapeutic action. Taking consideration of the selective action in the irradiation tumor area with PDT, and that it is a treatment that does not compromise other treatment options and presents reduced long-term morbidity when compared with chemotherapy or radiotherapy, this photo-assisted therapy is positioned as a main and/or adjuvant treatment in the fight against cancer. PDT has been approved by the Food Drug Administration (FDA), and also by other regulatory agencies around the world, to treat a variety of tumors and malignancies in the clinic [3]. For the success of PDT, three elements must converge in tumor cells: photosensitizer (PS) accumulation, light irradiation penetration and the presence of molecular oxygen. More of the recent developments regarding PDT have been made around the generation of new PSs.
Fil: Ibarra, Luis Exequiel. Universidad Nacional de Rio Cuarto. Facultad de Cs.exactas Fisicoquimicas y Naturales. Instituto de Biotecnologia Ambiental y Salud. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Conicet - Cordoba. Instituto de Biotecnologia Ambiental y Salud.; Argentina. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Departamento de Biología Molecular; Argentina
description Cancer is one of the major public health problems worldwide. According to the International Agency for Research on Cancer, an estimated 19.3 million new cancer cases and almost 10 million cancer deaths occurred in 2020 [1]. Furthermore, the diagnosis and treatment of cancer have been hampered by the coronavirus disease 2019 (COVID-19) pandemic and it is expected to result in an increased cancer mortality over the next years due to a delay in the diagnoses, and also due to an interruption in the treatments that had been applied to cancer patients. For example, the U.S. National Cancer Institute estimated a 1% increase in deaths related to breast and colorectal cancer over the next 10 years, the equivalent of approximately 10,000 more deaths, due to the impact of the pandemic [2]. This highlights the need to continue in the search of new therapeutic compounds in order to reduce the chance of cancer recurrence after traditional treatments such as surgery and radiotherapy.Some of these new treatments could be used as primary or adjuvant therapeutic options, for instance, photodynamic therapy (PDT) arises as an improved treatment tool due to its highly effective, non-invasive and localized therapeutic action. Taking consideration of the selective action in the irradiation tumor area with PDT, and that it is a treatment that does not compromise other treatment options and presents reduced long-term morbidity when compared with chemotherapy or radiotherapy, this photo-assisted therapy is positioned as a main and/or adjuvant treatment in the fight against cancer. PDT has been approved by the Food Drug Administration (FDA), and also by other regulatory agencies around the world, to treat a variety of tumors and malignancies in the clinic [3]. For the success of PDT, three elements must converge in tumor cells: photosensitizer (PS) accumulation, light irradiation penetration and the presence of molecular oxygen. More of the recent developments regarding PDT have been made around the generation of new PSs.
publishDate 2022
dc.date.none.fl_str_mv 2022-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/202086
Ibarra, Luis Exequiel; Development of nanosystems for active tumor targeting in photodynamic therapy; Newlands Press Ltd; Therapeutic Delivery; 13; 2; 2-2022; 71-74
2041-5990
2041-6008
CONICET Digital
CONICET
url http://hdl.handle.net/11336/202086
identifier_str_mv Ibarra, Luis Exequiel; Development of nanosystems for active tumor targeting in photodynamic therapy; Newlands Press Ltd; Therapeutic Delivery; 13; 2; 2-2022; 71-74
2041-5990
2041-6008
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.4155/tde-2021-0083
info:eu-repo/semantics/altIdentifier/url/https://www.future-science.com/doi/10.4155/tde-2021-0083
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Newlands Press Ltd
publisher.none.fl_str_mv Newlands Press Ltd
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846782501561827328
score 12.982451